Sagimet Biosciences Inc (NASDAQ: SGMT) kicked off on Tuesday, up 7.20% from the previous trading day, before settling in for the closing price of $5.42. Over the past 52 weeks, SGMT has traded in a range of $2.13-$20.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 43.11%. With a float of $21.13 million, this company’s outstanding shares have now reached $21.38 million.
Let’s look at the performance matrix of the company that is accounted for 10 employees. In terms of profitability, gross margin is 98.25%, operating margin of -1813.75%, and the pretax margin is -1462.55%.
Sagimet Biosciences Inc (SGMT) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Sagimet Biosciences Inc is 34.36%, while institutional ownership is 53.34%. The most recent insider transaction that took place on Jul 23 ’24, was worth 74,830. In this transaction Executive Chairman of this company sold 23,625 shares at a rate of $3.17, taking the stock ownership to the 118,693 shares. Before that another transaction happened on Jul 19 ’24, when Company’s Chief Medical Officer sold 8,357 for $3.10, making the entire transaction worth $25,910. This insider now owns 81,213 shares in total.
Sagimet Biosciences Inc (SGMT) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.35 earnings per share (EPS), higher than consensus estimate (set at -0.99) by 0.64. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 43.11% per share during the next fiscal year.
Sagimet Biosciences Inc (NASDAQ: SGMT) Trading Performance Indicators
Take a look at Sagimet Biosciences Inc’s (SGMT) current performance indicators. Last quarter, stock had a quick ratio of 29.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 89.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.14, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -3.55 in one year’s time.
Technical Analysis of Sagimet Biosciences Inc (SGMT)
Sagimet Biosciences Inc (NASDAQ: SGMT) saw its 5-day average volume 0.91 million, a negative change from its year-to-date volume of 1.13 million. As of the previous 9 days, the stock’s Stochastic %D was 43.17%. Additionally, its Average True Range was 0.52.
During the past 100 days, Sagimet Biosciences Inc’s (SGMT) raw stochastic average was set at 87.24%, which indicates a significant increase from 64.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.55% in the past 14 days, which was lower than the 105.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.07, while its 200-day Moving Average is $4.79. Nevertheless, the first resistance level for the watch stands at $6.00 in the near term. At $6.18, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.51. If the price goes on to break the first support level at $5.49, it is likely to go to the next support level at $5.16. Assuming the price breaks the second support level, the third support level stands at $4.98.
Sagimet Biosciences Inc (NASDAQ: SGMT) Key Stats
The company with the Market Capitalisation of 178.22 million has total of 30,675K Shares Outstanding. Its annual sales at the moment are 2,000 K in contrast with the sum of -27,880 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -8,120 K.
